Clinical trials
Locally Advanced Gastric Cancer clinical trials
Below are recruiting locally advanced gastric cancer clinical trials, each written for real people, not researchers. We’re tracking 309 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06787911RecruitingPhase 2
Donafenib and immunotherapy before surgery for advanced thyroid cancer
This trial tests a combination of two drugs—donafenib (a targeted therapy) and an immunotherapy (anti-PD-1 antibody)—given before surgery for locally advanced differentiated thyroid cancer. The goal is to shrink the tumor to make surgery easier and more complete. If you have this type of thyroid cancer that is hard to remove completely with surgery alone, this study may be an option.
ShanghaiAges 18–80 - NCT06791083RecruitingPhase 2
Envafolimab, Fruquintinib, and chemo before gastric cancer surgery
This trial tests a combination of two targeted drugs (Envafolimab and Fruquintinib) plus chemotherapy given before surgery for certain types of stomach cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Fuzhou, FujianAges 18–75 - NCT06791148RecruitingPhase 2
Low-dose radiation plus chemo and immunotherapy for advanced stomach cancer
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT06802666RecruitingPhase 2
Short radiation plus combo drugs for rectal cancer
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
HubeiAges 18–75 - NCT07432295RecruitingPhase 2
Givastomig plus nivolumab and chemo for advanced stomach cancer
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Goodyear, ArizonaAges 18 years+ - NCT07401199Recruiting
AI predicts immunotherapy response in advanced stomach cancer
This trial uses artificial intelligence to analyze CT scans, blood, and tumor tissue to predict how well your cancer will respond to chemotherapy and immunotherapy before surgery. It aims to personalize treatment for locally advanced stomach or gastroesophageal junction cancer.
Fuyang, AnhuiAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07392892RecruitingPhase 2/Phase 3
Study of PF-08634404 plus chemo for stomach and esophagus cancer
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Atascadero, CaliforniaAges 18 years+ - NCT06830018Recruiting
New megestrol for advanced stomach or colon cancer with fatigue
This study tests a new form of megestrol (a medicine that can boost appetite and energy) for people with advanced stomach or colorectal cancer who also have fatigue and poor appetite. It is given as a first treatment, meaning you haven't had chemotherapy yet for your advanced cancer.
Shenyang, LiaoningAges 18–75 - NCT06405113RecruitingPhase 2
Fecal transplant, chemo, and immunotherapy for advanced stomach cancer
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
ChangzhouAges 18–80 - NCT07371663RecruitingPhase 1/Phase 2
TCC1727 combination therapy for advanced solid tumors
This trial tests a new drug, TCC1727, combined with other treatments for people with advanced solid tumors that have stopped responding to standard therapy. It aims to see if these combinations can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07334431RecruitingPhase 1/Phase 2
A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Zhengzhou, HenanAges 18–75 - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Sydney, New South WalesAges 18 years+ - NCT07325630RecruitingPhase 2
Perioperative study of IBI363 for MHC-II-negative advanced stomach cancer
This trial tests a new treatment called IBI363 given before and after surgery for people with a certain type of advanced stomach cancer that lacks the MHC-II marker. The goal is to see if it helps shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07320586RecruitingPhase 2
Carilizumab and chemo for advanced gastric cancer
This trial tests a combination of carilizumab (an immunotherapy) and albumin paclitaxel (a chemotherapy drug) for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line treatment. It aims to see if this second-line option can help control the cancer.
Jinan, ShandongAges 18–75 - NCT07315854RecruitingPhase 2
Immunotherapy combo plus chemo for untreated stomach cancer
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07298200RecruitingPhase 1
XH001 injection plus T-cells for advanced gastric cancer
This trial tests a new treatment combining an injection (XH001) with specially made immune cells (T-cells) that target your tumor's unique markers. It's for people with advanced stomach cancer who have not responded to standard therapies.
Nanjing, JiangsuAges 18–70 - NCT07294664RecruitingPhase 2
Drug combo trial for first treatment of advanced stomach cancer
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
Zhengzhou, HenanAges 18 years+ - NCT06288360RecruitingPhase 2
Chemo plus immunotherapy before surgery for PD-L1-negative cervical cancer
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
Hefei, AnhuiAges 18–70 - NCT07259226RecruitingPhase 2
Studying resistance to antibody-drug conjugates in advanced cancer
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
VillejuifAges 18 years+ - NCT07202364RecruitingPhase 2
Study of YL202 for advanced solid tumors
This trial tests a new drug called YL202 for people with advanced solid tumors (like lung, colon, or cervical cancer) who have already tried 1-2 standard treatments. It aims to see if YL202 can shrink tumors or slow their growth.
Changsha, HunanAges 18 years+ - NCT06925243RecruitingPhase 3
Apatinib, Sintilimab, and Chemo for Intestinal Gastric Cancer
This phase 3 trial tests adding the targeted drug apatinib to a standard combination of sintilimab (immunotherapy) and chemotherapy (SOX regimen) given before surgery for a specific type of stomach or gastroesophageal junction cancer (intestinal type, HER2-negative). The goal is to see if the three-drug combination works better than the two-drug combination in shrinking the tumor and improving outcomes before surgery.
Lanzhou, GansuAges 18–75 - NCT07194005RecruitingPhase 2
Combination therapy for HER2 1+/2+ advanced stomach cancer
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06940102Recruiting
A study on megestrol acetate for weight loss in advanced digestive cancer
This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).
Shenyang, LiaoningAges 18 years+
Hear when a new Locally Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced gastric cancer?
- Yes. Clin2 currently lists 309 recruiting locally advanced gastric cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced gastric cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced gastric cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.